News &amp; Updates

Treatment with cefdinir and cephalexin results in comparable failure rates, but patients on cephalexin tend to have more unplanned clinic and emergency visits, a study has shown.

Cefdinir vs cephalexin: Which is a better step-down therapy in severe UTI?

Original New Drug Application Approvals by US FDA (1-15 July 2026)

New drug applications approved by US FDA as of 1-15 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 July 2026)

Buprenorphine a viable option for acute pain in ICU patients

The use of intravenous (IV) buprenorphine appears to be a good substitute for full agonist IV opioids for managing pain in the medical intensive care unit (ICU), suggests a study.

Buprenorphine a viable option for acute pain in ICU patients

Lithium use during pregnancy ups risk of preterm birth

Pregnant women who are using lithium are at increased risk of spontaneous preterm birth, according to a retrospective study.

Lithium use during pregnancy ups risk of preterm birth

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026 by

The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026

Prophylactic vitamin K refusal may have adverse consequences for newborns

25 Jul 2026

The number of infants not receiving intramuscular vitamin K to prevent bleeding episodes is increasing, and this translates to an increased risk of bleeding episodes, including intracranial haemorrhages, according to a nationwide cohort study from Sweden.

Prophylactic vitamin K refusal may have adverse consequences for newborns

25 Jul 2026

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

Treatment with carvedilol, compared with nadolol or propranolol, results in reduced rates of major decompensation events among patients with cirrhosis, a study has shown.

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

Survodutide promotes weight loss in adults with obesity

In patients with obesity but without diabetes, treatment with survodutide results in substantial reductions in body weight compared with placebo, according to the phase III SYNCHRONIZE-1 trial.

Survodutide promotes weight loss in adults with obesity

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026 by

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.

Venglustat superior to ERT in Gaucher disease type 3